Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01316185 · ClinicalTrials.gov registry record · Phase 1
Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)
A Phase 1 study, sponsored by Eiger BioPharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01316185: Clinical Trial Phase 1 study, sponsored by Eiger BioPharmaceuticals.
NCT01316185 is a Phase 1 study that was terminated before completion, run by Eiger BioPharmaceuticals. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01316185, a Phase 1 study, was terminated before completion, sponsored by Eiger BioPharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the optimal dose of EBP921 by comparing the efficacy and safety of 2 dose regimens in patients with chronic HDV.
Primary Outcome
The primary efficacy endpoint will be the median change in HDV-RNA from baseline to HDV RNA nadir as measured by quantitative PCR during the 28-day dosing period.
Interventions
- DRUG EBP921
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Why NCT01316185 stopped before completion
NCT01316185 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which EBP921 is the first listed.
NCT01316185 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01316185 about?
NCT01316185 is a clinical study titled "Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)". The purpose of this study is to assess the optimal dose of EBP921 by comparing the efficacy and safety of 2 dose regimens in patients with chronic HDV.
What is the current status of trial NCT01316185?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-01. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01316185?
The interventions under investigation include: EBP921 (DRUG).
Who is sponsoring clinical trial NCT01316185?
This trial is sponsored by Eiger BioPharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01316185's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia